Please upgrade your browser.
Immunohistochemical stains have greatly improved the diagnostic accuracy of renal cell carcinoma (RCC) for primary and distant tumours. We evaluate a marker that has recently been incorporated in clinical practice, PAX-8, in primary and metastatic RCCs.
We combined differentially expressed genes, pathways and network analyses to gain new insights into the underlying molecular mechanisms of the disease development.
In cases of clear cell renal cell carcinoma – the most common type of renal cell carcinoma – the cancer cells become fatty.
The purpose of this study was to assess the influence of region of interest (ROI) size and positioning on perfusion and permeability parameters as well as on interobserver and intraobserver variability of dynamic contrast-enhanced (DCE-MRI) of primary renal cell carcinoma (RCC) and metastases.
Patients with operable kidney cancers were more likely to have a partial nephrectomy -- the recommended treatment for localized tumors -- when treated in hospitals that were early adopters of robotic surgery, according to a new study.
Ono Pharma, Bristol-Myers & Kyowa Hakko Kirin enter pact to condutct phase 1 combo study with Opdivo & mogamulizumab in advanced solid tumors
Ono Pharmaceutical Co.,Ltd., Bristol-Myers Squibb Company and Kyowa Hakko Kirin Co., Ltd. have entered into a clinical trial collaboration agreement to conduct a phase 1 combination study with Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor, and mogamulizumab, an anti-CCR4 antibody.
Research Led By NYU Langone Medical Center Shows Greater Experience Utilizing Robotic Surgery Leads to Better Use for Partial Nephrectomies
Being an extrovert can boost your immune system, but conscientiousness and being open can...
A drug approved to treat kidney cancer actually targeted that gene. Within two weeks of taking it, Wartman’s cancer was gone.
Once this is done, demand for these tests is expected to increase.
|Powered by NeonCRM|